TW319769B - - Google Patents

Download PDF

Info

Publication number
TW319769B
TW319769B TW084106000A TW84106000A TW319769B TW 319769 B TW319769 B TW 319769B TW 084106000 A TW084106000 A TW 084106000A TW 84106000 A TW84106000 A TW 84106000A TW 319769 B TW319769 B TW 319769B
Authority
TW
Taiwan
Prior art keywords
group
item
carboxylic acid
salt
patent application
Prior art date
Application number
TW084106000A
Other languages
English (en)
Chinese (zh)
Original Assignee
Dai Nippon Seiyaku Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dai Nippon Seiyaku Kk filed Critical Dai Nippon Seiyaku Kk
Application granted granted Critical
Publication of TW319769B publication Critical patent/TW319769B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TW084106000A 1994-06-14 1995-06-13 TW319769B (enExample)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP15657894 1994-06-14
JP19792194 1994-07-28
JP30691494 1994-11-15
JP33995694 1994-12-28
JP8170595 1995-03-13

Publications (1)

Publication Number Publication Date
TW319769B true TW319769B (enExample) 1997-11-11

Family

ID=27524935

Family Applications (1)

Application Number Title Priority Date Filing Date
TW084106000A TW319769B (enExample) 1994-06-14 1995-06-13

Country Status (26)

Country Link
US (1) US5817669A (enExample)
EP (1) EP0787726B1 (enExample)
JP (1) JP3391796B2 (enExample)
KR (1) KR100350921B1 (enExample)
CN (1) CN1053668C (enExample)
AT (1) ATE209645T1 (enExample)
AU (1) AU679859B2 (enExample)
BR (1) BR9508037A (enExample)
CA (1) CA2192824C (enExample)
CZ (1) CZ292631B6 (enExample)
DE (1) DE69524251T2 (enExample)
DK (1) DK0787726T3 (enExample)
ES (1) ES2163512T3 (enExample)
FI (1) FI112485B (enExample)
HU (1) HU220072B (enExample)
MX (1) MX9606331A (enExample)
NO (1) NO307255B1 (enExample)
NZ (1) NZ287139A (enExample)
PL (1) PL181867B1 (enExample)
PT (1) PT787726E (enExample)
RO (1) RO117793B1 (enExample)
RU (1) RU2151770C1 (enExample)
SI (1) SI0787726T1 (enExample)
SK (1) SK281341B6 (enExample)
TW (1) TW319769B (enExample)
WO (1) WO1995034559A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2004112787A (ru) * 2001-09-26 2005-10-10 Байер Фармасьютикалс Корпорейшн (US) Производные 1,6-нафтиридина как противодиабетические средства
US6802423B2 (en) * 2002-02-20 2004-10-12 Trans Global Foods, Inc. Disposable food delivery apparatus
EP1610795A4 (en) * 2003-04-07 2007-10-24 Cylene Pharmaceuticals Inc HETEROCYCLIC SUBSTITUTED 1,4-DIHYDRO-4-OXO-1,8-NAPHTHPYRIDINE ANALOGUE
SG144936A1 (en) * 2003-09-10 2008-08-28 Kyorin Seiyaku Kk 7-(4-substituted-3-cyclopropylaminomethyl-1- pyrrolidinyl)quinolonecarboxylic acid derivative
DE10352979A1 (de) * 2003-11-13 2005-06-09 Merck Patent Gmbh Pyridopyrimidinone
AU2013201203C1 (en) * 2004-03-15 2015-04-23 Sumitomo Dainippon Pharma Co., Ltd. Sns-595 and methods of using the same
DE602005018333D1 (de) * 2004-03-15 2010-01-28 Sunesis Pharmaceuticals Inc Sns-595 und anwendungsverfahren
CN101039939B (zh) * 2004-10-14 2010-07-07 霍夫曼-拉罗奇有限公司 作为cdk1抑制剂的喹唑啉基亚甲基噻唑啉酮类
EP1805174A1 (en) * 2004-10-14 2007-07-11 F.Hoffmann-La Roche Ag 1,5-naphthyridine azolidinones having cdk1 antiproliferative activity
RU2420524C2 (ru) * 2005-05-19 2011-06-10 Дайити Санкио Компани, Лимитед Производные три- или тетра-замещенного-3-аминопирролидина
US7563805B2 (en) 2005-05-19 2009-07-21 Daiichi Pharmaceutical Co., Ltd. Tri-, tetra-substituted-3-aminopyrrolidine derivative
US20070117770A1 (en) * 2005-08-19 2007-05-24 Cylene Pharmaceuticals, Inc. Human ribosomal DNA (rDNA) and ribosomal RNA (rRNA) nucleic acids and uses thereof
AU2013219242C1 (en) * 2005-09-02 2016-09-22 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
KR20080041298A (ko) * 2005-09-02 2008-05-09 선에시스 파마슈티컬스 인코포레이티드 암 치료를 위한(＋)-1,4-디히드로-7-[(3ｓ,4ｓ)-3-메톡시-4-(메틸아미노)-1-피롤리디닐]-4-옥소-1-(2-티아졸릴)-1,8-나프티리딘-3-카르복실산의 사용 방법
CN104873502A (zh) * 2005-09-02 2015-09-02 逊尼希思制药公司 使用(+)-1,4-二氢-7-[(3s,4s)-3-甲氧基-4-(甲氨基)-1-吡咯烷基]-4-氧代-1-(2-噻唑基)-1,8-萘啶-3-羧酸治疗癌症的方法
RU2428983C2 (ru) * 2005-09-02 2011-09-20 Санесис Фармасьютикалз, Инк. Способы применения (+)-1,4-дигидро-7-[(3s,4s)-3-метокси-4-(метиламино)-1-пирролидинил]-4-оксо-1-(2-тиазолил)-1,8-нафтиридин-3-карбоновой кислоты для лечения рака
CA2845095A1 (en) * 2005-09-02 2007-03-08 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
US8580814B2 (en) * 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
TW200800983A (en) 2005-09-14 2008-01-01 Janssen Pharmaceutica Nv 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
US7642270B2 (en) 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
CN101305000A (zh) * 2005-09-14 2008-11-12 詹森药业有限公司 作为c-fms激酶抑制剂的5-氧代-5,8-二氢-吡啶并-嘧啶类
CN104027333B (zh) * 2006-06-12 2017-05-17 逊尼希思制药公司 治疗癌症的化合物和组合物
US20100048609A1 (en) * 2006-08-01 2010-02-25 Jacobs Jeffrey W Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
EP2049109B1 (en) 2006-08-02 2015-11-18 Sunesis Pharmaceuticals, Inc. Combined use of (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid and cytarabine (ara-c) for the treatment of leukemia
MX2010004350A (es) * 2007-10-22 2010-05-19 Sunesis Pharmaceuticals Inc Metodos de uso del acido (+)-1,4-dihidro-7-[(3s,4s)]-3-metoxi-4-(m etilamino)-1-pirrolidinil-4-oxo-1-(2-tiazolil)-1, 8-naftiridina-3-carboxilico en terapias de combinacion.
EP2249831A2 (en) 2007-12-10 2010-11-17 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-ý(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl¨-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
CA2748066C (en) * 2008-12-31 2017-06-27 Anantha Sudhakar Method of preparing (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
SG173855A1 (en) 2009-02-27 2011-09-29 Sunesis Pharmaceuticals Inc Methods of using sns-595 for treatment of cancer subjects with reduced brca2 activity
UA110465C2 (en) 2009-09-04 2016-01-12 Sunesis Pharmaceutecals Inc Stable sns-595 composition
TW201120037A (en) * 2009-10-26 2011-06-16 Sunesis Pharmaceuticals Inc Compounds and methods for treatment of cancer
KR102001364B1 (ko) * 2011-05-13 2019-07-22 어레이 바이오파마 인크. Trka 키나제 저해제로서의 피롤리디닐 유레아 및 피롤리디닐 티오유레아 화합물
CN103497186B (zh) * 2013-09-24 2015-02-25 浙江司太立制药股份有限公司 含有烷氧亚氨基取代的萘啶酮羧酸衍生物及其制备方法
ES2988457T3 (es) * 2017-03-24 2024-11-20 Wakunaga Pharma Co Ltd Derivado novedoso del ácido piridona carboxílico o sal del mismo

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3988463A (en) * 1974-05-06 1976-10-26 Merck & Co., Inc. Method of preventing metastasis of H. Ep. No. 3
US4384001A (en) * 1978-12-21 1983-05-17 Gosalvez Mario Treatment of tumors with thiazolidine-4-carboxylic acid
US4730000A (en) * 1984-04-09 1988-03-08 Abbott Laboratories Quinoline antibacterial compounds
EP0154780B1 (en) * 1984-01-26 1990-04-11 Abbott Laboratories Quinoline antibacterial compounds
NZ210847A (en) * 1984-01-26 1988-02-29 Abbott Lab Naphthyridine and pyridopyrimidine derivatives and pharmaceutical compositions
JPS61152682A (ja) * 1984-12-27 1986-07-11 Dainippon Pharmaceut Co Ltd ピリドンカルボン酸誘導体、そのエステルおよびその塩
JPS61251667A (ja) * 1985-04-30 1986-11-08 Otsuka Pharmaceut Co Ltd ベンゾヘテロ環化合物
IL79110A0 (en) * 1985-06-13 1986-09-30 Schering Corp Polycyclic quinoline,naphthyridine and pyrazinopyridine derivatives
EP0226624A1 (en) * 1985-06-14 1987-07-01 The Upjohn Company Cyclopentapyrazole and tetrahydroindazole compounds
JPS6233176A (ja) * 1985-08-05 1987-02-13 Toyama Chem Co Ltd １，４−ジヒドロ−４−オキソナフチリジン誘導体およびその塩
JP2704428B2 (ja) * 1988-06-15 1998-01-26 富山化学工業株式会社 キノロンカルボン酸誘導体またはその塩
DE3906365A1 (de) * 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
JPH06233176A (ja) * 1993-01-29 1994-08-19 Sony Corp ビデオカメラ

Also Published As

Publication number Publication date
HU9603455D0 (en) 1997-02-28
CA2192824A1 (en) 1995-12-21
HK1000495A1 (en) 2002-07-19
JP3391796B2 (ja) 2003-03-31
DK0787726T3 (da) 2002-02-11
CZ292631B6 (cs) 2003-11-12
SK281341B6 (sk) 2001-02-12
EP0787726A1 (en) 1997-08-06
BR9508037A (pt) 1997-09-16
CN1053668C (zh) 2000-06-21
SK157496A3 (en) 1997-08-06
CA2192824C (en) 2006-11-07
FI965020A7 (fi) 1996-12-16
HUT75777A (en) 1997-05-28
PL181867B1 (pl) 2001-09-28
CZ364396A3 (en) 1997-06-11
PT787726E (pt) 2002-04-29
NZ287139A (en) 1997-07-27
RU2151770C1 (ru) 2000-06-27
NO965305L (no) 1997-02-04
FI965020A0 (fi) 1996-12-13
RO117793B1 (ro) 2002-07-30
FI112485B (fi) 2003-12-15
MX9606331A (es) 1997-03-29
PL317726A1 (en) 1997-04-28
NO307255B1 (no) 2000-03-06
AU679859B2 (en) 1997-07-10
CN1158614A (zh) 1997-09-03
ES2163512T3 (es) 2002-02-01
SI0787726T1 (en) 2002-04-30
WO1995034559A1 (en) 1995-12-21
ATE209645T1 (de) 2001-12-15
EP0787726A4 (enExample) 1997-08-06
EP0787726B1 (en) 2001-11-28
NO965305D0 (no) 1996-12-11
US5817669A (en) 1998-10-06
KR100350921B1 (ko) 2002-11-18
DE69524251T2 (de) 2002-07-11
DE69524251D1 (de) 2002-01-10
HU220072B (hu) 2001-10-28
AU2576795A (en) 1996-01-05

Similar Documents

Publication Publication Date Title
RU2151770C1 (ru) Производные пиридонкарбоновой кислоты, способы их получения, противоопухолевое средство и фармацевтическая композиция
TWI338684B (en) Tetrahydroquinoline derivatives and a process for preparing the same
JPWO1995034559A1 (ja) 新規化合物、その製法および抗腫瘍剤
WO2023280237A1 (zh) 一种磷酸酶降解剂的合成和应用
JP4323574B2 (ja) 抗腫瘍剤
WO2020216190A1 (zh) 一种喹唑啉化合物及其在医药上的应用
WO2023143352A1 (zh) 一种含氮杂环化合物、其制备方法及应用
CN109803968A (zh) 吡啶并嘧啶酮cdk2/4/6抑制剂
CN109715634A (zh) Menin-mll相互作用的稠合二环抑制剂
AU2014294866B2 (en) Novel derivatives of indole and pyrrole, method for the production thereof and pharmaceutical compositions containing same
CN108707140A (zh) 蛋白酶c抑制剂
CN109803651A (zh) 免疫调节剂化合物
TW200813022A (en) Organic compounds
CN109641882A (zh) 作为nik抑制剂的杂芳族衍生物
TW202003487A (zh) 經取代的２，２＇—聯嘧啶基化合物、其類似物及其使用方法
CN107304211A (zh) 一种选择性fgfr4激酶抑制剂
US20030119848A1 (en) Anti acid-fast bacterial agent containing pyridonecarboxylic acids as active ingredient
TW201736367A (zh) 6,7,8,9-四氫-5H-吡啶并[2,3-d]氮呯多巴胺D3配體
CN104540806B (zh) 作为bir2和/或bir3抑制剂的氮杂杂环
TWI229079B (en) Tetrahydroquinoline derivatives, pharmaceutical composition comprising them and process for the preparation of the same
BRPI0710538A2 (pt) processo para a sìntese de um estereoisÈmero substancialmente puro, compostos, composição farmacêutica que compreende um composto, processo para a sìntese de um composto e uso do mesmo.
WO1998048801A1 (en) 2-azabicyclo compounds
JP5079612B2 (ja) 抗腫瘍剤
CN109311875A (zh) 作为PI3Kβ抑制剂的二环吡啶、二环吡嗪、和二环嘧啶衍生物
TW201400470A (zh) ４－烷醇胺－３－吡唑哢衍生物

Legal Events

Date Code Title Description
MK4A Expiration of patent term of an invention patent